Loading...

NEXTGEN PULMOCORE 12 GENE PANEL (SP142)

image not found

NABL Cap Accredited 
The NextGen PulmoCore 12 Gene Panel (SP142) at Metropolis Healthcare is a focused molecular and immunohistochemistry-based test designed to evaluate key genetic alterations and PD-L1 expression relevant to lung cancers. This panel analyzes 12 clinically significant genes using advanced NGS technology, combined with PD-L1 assessment using the SP142 clone. Metropolis Healthcare delivers precise, actionable insights to help guide targeted therapy and immunotherapy decisions. It is ideal for patients newly diagnosed with lung cancer or those requiring therapy optimization.

  • 17 Crores+ Samples Processed
  • World Class Technology Labs
  • 25+ Years of Trust & Experience
  • Free Home Collection

Price: Rs. 25,000.00

Sample Type: Tissue

Fasting Not Required


Notes:N8193

Frequently Asked Questions (FAQ's):

What does the NextGen PulmoCore 12 Gene Panel (SP142) at Metropolis Healthcare include?
It covers 12 important lung cancer–related genes and PD-L1 SP142 expression to support treatment planning.

How does Metropolis Healthcare perform this lung cancer panel?
Metropolis Healthcare uses high-depth NGS for gene analysis and validated SP142 immunohistochemistry for PD-L1 scoring.

Who should consider taking this test at Metropolis Healthcare?
Patients with suspected or confirmed lung cancer who require targeted or immunotherapy evaluation should take this panel.

Is fasting required for this test at Metropolis Healthcare?
No fasting is needed; the test is performed on tumor tissue and/or blood samples as recommended.

How long do results take at Metropolis Healthcare?
Results typically take 2–3 weeks due to detailed genomic and PD-L1 analysis.

Can this test at Metropolis Healthcare help identify suitable treatments?
Yes, it assists in identifying targeted therapy options and determining potential benefit from immunotherapy.

How accurate is the genetic analysis performed by Metropolis Healthcare?
Metropolis Healthcare ensures high analytical accuracy with deep sequencing coverage and strict quality controls.

Does PD-L1 SP142 testing at Metropolis Healthcare support immunotherapy decisions?
Yes, SP142 scoring helps clinicians evaluate eligibility and potential response to PD-L1–based treatments.

OUR corporates PARTNER

Feedback

Patient's Testimonials

Trusted by Thousands

OUR Accreditations

OUR Lab